It's tough times at Eli Lilly with patents ending, failed drugs, among other problems, reports the New York Times. But CEO John Lechleiter says that Lilly doesn't need to turn to mergers or acquisitions to jump-start the company; he says they can rely on in-house research and cost-cutting. "At a time when others say Lilly has to do a deal or Lilly has to go outside itself to solve its problems, we're resolutely focused on what we have to do inside the company," Lechleiter says. The Times points out that "some analysts do not share his optimism" as the company has "virtually no new products to market until 2013, when it hopes to start rolling out two a year."
Life at Lilly
Oct 05, 2010